LUTREPULSE KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUTREPULSE KIT (LUTREPULSE KIT).
LUTREPULSE (gonadorelin acetate) is a synthetic decapeptide analog of endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on the anterior pituitary gonadotroph cells, stimulating synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In males, LH stimulates Leydig cells to produce testosterone; in females, LH triggers ovulation and FSH stimulates follicular development.
| Metabolism | Gonadorelin is rapidly cleaved by peptidases in plasma and tissues, primarily at the Gly-Leu bond, producing inactive metabolites. Renal excretion accounts for the majority of elimination, with less than 10% excreted unchanged. |
| Excretion | Renal: 10% unchanged; hepatic metabolism, metabolites primarily excreted in bile (70%) and feces. |
| Half-life | 3 hours (initial phase), terminal elimination half-life 10-12 hours; clinically, steady-state reached within 2 days. |
| Protein binding | 60-70% bound to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | 0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous: 100% (relative to IV); Intramuscular: 94%. |
| Onset of Action | Intravenous: 5-10 minutes; Subcutaneous: 30-60 minutes. |
| Duration of Action | Intravenous: 4-6 hours; Subcutaneous: 8-12 hours; effect duration dose-dependent. |
| Molecular Weight | 1182.32 |
5 mcg subcutaneously every 90 minutes via pulsatile pump.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required based on GFR. |
| Liver impairment | No dose adjustment required for Child-Pugh class A, B, or C. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No specific dose adjustment; use with caution due to limited data. |
| 1st trimester | Lutrepulse (gonadorelin acetate) is not indicated for use during pregnancy. Limited human data; animal studies show no teratogenic effects at therapeutic doses. Use only if clearly needed and potential benefit justifies risk. |
| 2nd trimester | No well-controlled studies in pregnant women. Not intended for use during pregnancy. Consider discontinuing if pregnancy occurs. |
| 3rd trimester | Not indicated during pregnancy. Potential adverse effects on fetus unknown; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for LUTREPULSE KIT (LUTREPULSE KIT).
| Placental transfer | Gonadorelin is a decapeptide with molecular weight 1182.32 Da, and would be expected to cross the placenta to some extent, though specific studies are lacking. Its small size and peptide nature suggest potential transfer, but clinical relevance is unclear. |
| Breastfeeding | It is unknown if gonadorelin is excreted in human milk. Caution should be exercised when administered to a nursing woman. The molecular weight suggests possible excretion, but clinical significance is likely low. Consider alternative therapies if breastfeeding. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Hypersensitivity to gonadorelin or any component of the kitPregnancy (due to lack of necessity and potential risk)Undiagnosed abnormal vaginal bleeding (unless appropriate diagnostic evaluation completed)
| Precautions | Hypersensitivity reactions (anaphylaxis, urticaria, angioedema) have been reported; discontinue if serious reaction occurs., Ovarian hyperstimulation syndrome (OHSS) may occur in women undergoing ovulation induction; monitor for abdominal pain, distention, nausea, and rapid weight gain., Multiple gestation pregnancy risk increased (especially with ovulation induction)., Use caution in patients with pituitary adenoma; stimulate LH/FSH release may precipitate infarction., Not intended for long-term therapy; prolonged use may lead to desensitization of pituitary gonadotrophs. |
| Food/Dietary | No specific food interactions are known for lutropin alfa. Maintain a normal diet unless advised otherwise by your healthcare provider. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | LUTREPULSE KIT (gonadorelin acetate) is not indicated for use during pregnancy. Fetal risk cannot be excluded; no adequate human data. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, use during pregnancy may disrupt the normal hormonal milieu and theoretically affect fetal development, particularly in the first trimester. |
| Fetal Monitoring | If inadvertent exposure occurs during pregnancy, monitor fetal development with ultrasound and assess for potential hormonal disruption. No specific monitoring guidelines exist. |
| Fertility Effects | LUTREPULSE KIT is used to induce ovulation in women with hypothalamic amenorrhea. It can restore fertility. Ovarian hyperstimulation syndrome (OHSS) and multiple gestations are possible risks. Discontinue use upon confirmed pregnancy. |
| Clinical Pearls | In women with hypogonadotropic hypogonadism, confirm endogenous LH/FSH deficiency with low gonadotropins and estradiol, and exclude other causes of anovulation. Administer exactly as prescribed by the pulsatile pump; timing is critical. Monitor for ovarian hyperstimulation and multiple pregnancies. Discontinue if ovarian enlargement or pregnancy occurs. |
| Patient Advice | Administer the intravenous or subcutaneous infusion as directed using the provided pump and supplies. · Report any signs of ovarian hyperstimulation (abdominal pain, bloating, nausea, rapid weight gain) immediately. · Use this kit only under the supervision of a fertility specialist. · Understand that multiple gestation is possible and discuss with your healthcare provider. · Do not interrupt therapy without consulting your doctor; missed doses may reduce success. |